Indegene (INDGN) Stock Overview
Operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for INDGN from our risk checks.
INDGN Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Indegene Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹579.75 |
| 52 Week High | ₹735.00 |
| 52 Week Low | ₹499.00 |
| Beta | 0 |
| 1 Month Change | 4.84% |
| 3 Month Change | 2.16% |
| 1 Year Change | -15.49% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 28.26% |
Recent News & Updates
Recent updates
Getting In Cheap On Indegene Limited (NSE:INDGN) Is Unlikely
Jul 23
M&A And Cortex Integration Will Expand Enterprise Opportunities
M&A activities and AI integration signal innovation and efficiency, likely boosting topline growth and improving net margins through cost reductions.Indegene Limited (NSE:INDGN) Annual Results: Here's What Analysts Are Forecasting For This Year
May 03Indegene Limited's (NSE:INDGN) Price Is Out Of Tune With Earnings
Feb 25Shareholder Returns
| INDGN | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 0.8% | 1.8% | 1.5% |
| 1Y | -15.5% | -0.4% | -4.7% |
Return vs Industry: INDGN underperformed the Indian Life Sciences industry which returned -3.2% over the past year.
Return vs Market: INDGN underperformed the Indian Market which returned -6% over the past year.
Price Volatility
| INDGN volatility | |
|---|---|
| INDGN Average Weekly Movement | 3.5% |
| Life Sciences Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: INDGN has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: INDGN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 4,158 | Manish Gupta | www.indegene.com |
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies.
Indegene Limited Fundamentals Summary
| INDGN fundamental statistics | |
|---|---|
| Market cap | ₹139.14b |
| Earnings (TTM) | ₹4.35b |
| Revenue (TTM) | ₹29.24b |
Is INDGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDGN income statement (TTM) | |
|---|---|
| Revenue | ₹29.24b |
| Cost of Revenue | ₹624.00m |
| Gross Profit | ₹28.61b |
| Other Expenses | ₹24.26b |
| Earnings | ₹4.35b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 18.14 |
| Gross Margin | 97.87% |
| Net Profit Margin | 14.89% |
| Debt/Equity Ratio | 3.9% |
How did INDGN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 06:54 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indegene Limited is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Deep Shah | Batlivala & Karani Securities India Pvt. Ltd. |
| Rajiv Berlia | Citigroup Inc |
| Ruchi Burde Mukhija | ICICI Securities Ltd. |